Mesoblast is a regenerative medicine company focused on developing allogeneic cellular therapies for severe and life-threatening inflammatory conditions. The company advances a clinical and translational pipeline supported by manufacturing, regulatory, and global trial capabilities.
Core Offerings
- Allogeneic cellular medicine platform technologies
- Clinical-stage therapy programs for immune and inflammatory disease areas
- Scientific and medical collaboration across treatment and research networks
Capabilities
- Cell therapy process development and translational science
- Multi-region clinical development and regulatory operations
- Partnership-led commercialization and market access planning
Commercial Model
Mesoblast follows a biopharma model built on R&D, clinical validation, and selective commercialization or partnership pathways for advanced cellular therapies.